These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 20169998)

  • 1. [Novel metabolic pathway of glucosylceramide that involves Klotho-related protein KLrP].
    Hayashi Y; Okino N; Ito M
    Seikagaku; 2010 Jan; 82(1):47-53. PubMed ID: 20169998
    [No Abstract]   [Full Text] [Related]  

  • 2. [Novel catabolic pathway of glycosphingolipids that includes a cytosolic glucocerebrosidase, klotho-related protein (KLrP)].
    Hayashi Y; Okino N; Kakuta Y; Ito M
    Tanpakushitsu Kakusan Koso; 2008 Sep; 53(12 Suppl):1462-7. PubMed ID: 21089349
    [No Abstract]   [Full Text] [Related]  

  • 3. Klotho-Related Protein KLrP: Structure and Functions.
    Hayashi Y; Ito M
    Vitam Horm; 2016; 101():1-16. PubMed ID: 27125736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Klotho-related protein is a novel cytosolic neutral beta-glycosylceramidase.
    Hayashi Y; Okino N; Kakuta Y; Shikanai T; Tani M; Narimatsu H; Ito M
    J Biol Chem; 2007 Oct; 282(42):30889-900. PubMed ID: 17595169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from glucosylceramide and Gaucher's disease.
    Luft FC
    J Mol Med (Berl); 1998 Oct; 76(11):723-4. PubMed ID: 9826117
    [No Abstract]   [Full Text] [Related]  

  • 6. L-glucosylceramide: synthesis, properties, and resistance to catabolism by glucocerebrosidase in vitro.
    Gal AE; Pentchev PG; Massey JM; Brady RO
    Proc Natl Acad Sci U S A; 1979 Jul; 76(7):3083-6. PubMed ID: 290986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease.
    McEachern KA; Fung J; Komarnitsky S; Siegel CS; Chuang WL; Hutto E; Shayman JA; Grabowski GA; Aerts JM; Cheng SH; Copeland DP; Marshall J
    Mol Genet Metab; 2007 Jul; 91(3):259-67. PubMed ID: 17509920
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic inflammation in glucocerebrosidase-deficient mice with minimal glucosylceramide storage.
    Mizukami H; Mi Y; Wada R; Kono M; Yamashita T; Liu Y; Werth N; Sandhoff R; Sandhoff K; Proia RL
    J Clin Invest; 2002 May; 109(9):1215-21. PubMed ID: 11994410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ubiquitous transgene expression of the glucosylceramide-synthesizing enzyme accelerates glucosylceramide accumulation and storage cells in a Gaucher disease mouse model.
    Barnes S; Xu YH; Zhang W; Liou B; Setchell KD; Bao L; Grabowski GA; Sun Y
    PLoS One; 2014; 9(12):e116023. PubMed ID: 25551612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the pathogenesis of Gaucher's disease: tissue distribution and biliary excretion of [14C]L-glucosylceramide in rats.
    Tokoro T; Gal AE; Gallo LL; Brady RO
    J Lipid Res; 1987 Aug; 28(8):968-72. PubMed ID: 3668390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucosylceramide and related compounds in normal tissues and in Gaucher disease.
    Suzuki K
    Prog Clin Biol Res; 1982; 95():219-30. PubMed ID: 7122635
    [No Abstract]   [Full Text] [Related]  

  • 12. An evolutionary and structure-based docking model for glucocerebrosidase-saposin C and glucocerebrosidase-substrate interactions - relevance for Gaucher disease.
    Atrian S; López-Viñas E; Gómez-Puertas P; Chabás A; Vilageliu L; Grinberg D
    Proteins; 2008 Feb; 70(3):882-91. PubMed ID: 17803231
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide.
    Bodennec J; Pelled D; Riebeling C; Trajkovic S; Futerman AH
    FASEB J; 2002 Nov; 16(13):1814-6. PubMed ID: 12223447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitors and stimulators of glucocerebroside metabolism.
    Radin NS
    Prog Clin Biol Res; 1982; 95():357-83. PubMed ID: 6214799
    [No Abstract]   [Full Text] [Related]  

  • 15. Neuronal forms of Gaucher disease.
    Vitner EB; Futerman AH
    Handb Exp Pharmacol; 2013; (216):405-19. PubMed ID: 23563668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Generation of a conditional knockout of murine glucocerebrosidase: utility for the study of Gaucher disease.
    Sinclair GB; Jevon G; Colobong KE; Randall DR; Choy FY; Clarke LA
    Mol Genet Metab; 2007 Feb; 90(2):148-56. PubMed ID: 17079175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme replacement therapy for mild patients with Gaucher disease.
    Zimran A; Ilan Y; Elstein D
    Am J Hematol; 2009 Apr; 84(4):202-4. PubMed ID: 19229987
    [No Abstract]   [Full Text] [Related]  

  • 18. [Gaucher disease].
    Eto Y
    Nihon Rinsho; 2001 Mar; 59 Suppl 3():317-21. PubMed ID: 11347084
    [No Abstract]   [Full Text] [Related]  

  • 19. Glucocerebroside storage in normal monocyte cultures.
    Hardy B; Teitelman-Weissman B; Chazan S; Neri A
    Biomed Pharmacother; 1987; 41(1):40-4. PubMed ID: 3607254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gaucher's disease.
    Patel AL; Shaikh WA; Khobragade AK; Soni HG; Joshi AS; Sahasrabudhe GS; Chole PV
    J Assoc Physicians India; 2009 May; 57():410-1. PubMed ID: 19634291
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.